Candida Therapeutic Vaccine in Head and Neck Cancer Patients to Reduce Recurrence
Phase 2
100
about 5 years
18–100
6 sites in AR, NY
What this study is about
This trial is testing a Candida vaccine in people with head and neck cancer to see if it reduces the chance of the cancer coming back. The treatment involves receiving Candin or a placebo (saline solution) over two years, comparing recurrence rates between those who receive Candin versus those who receive the placebo.
Simplified from trial records by PatientMatch.
What you may be asked to do
- 1.Receive 0.5 mL Candin®/injection
- 2.Receive Placebo: 0.5 mL Intravenous 0.9% NaCl solution (Saline)
Participation Burden
What's physically and logistically required of participants.
Requires travel to a study site
How treatment is administered
You may get a placebo/standard care, and you won't know which.
Extracted study details
Pulled from the trial record to show what is being tested and what the study is measuring.
injection, intravenous
Secondary: Assessment of adverse events
Oncology